November 29, 2022 07:26 AM ESTUpdated 04:41 PM

New TIGIT data cut from Gilead, Arcus sets the stage for full readout

Amber Tong

Gilead and Arcus are once again declaring success for their TIGIT therapy without spelling out the data — although this time, they promise the numbers are …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

New TIGIT data cut from Gilead, Arcus sets the stage for full readout

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Gene editing startup Scribe Therapeutics lets go of staff as it preps for the clinic

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Resilience cuts 120 employees at a former bluebird gene therapy site

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

New TIG­IT da­ta cut from Gilead, Ar­cus sets the stage for full read­out

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

New TIGIT data cut from Gilead, Arcus sets the stage for full readout